Chan, Alexander
Haley, Rebecca M. http://orcid.org/0000-0001-7322-7829
Najar, Mohd Altaf
Gonzalez-Martinez, David
Bugaj, Lukasz J. http://orcid.org/0000-0002-0749-2912
Burslem, George M. http://orcid.org/0000-0002-2812-983X
Mitchell, Michael J. http://orcid.org/0000-0002-3628-2244
Tsourkas, Andrew http://orcid.org/0000-0001-7758-1753
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA241661)
National Science Foundation (GFRP, GRFP, CBET-2145491)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM138211, R35 GM142505)
Burroughs Wellcome Fund
U.S. Department of Health & Human Services | National Institutes of Health (DP2 TR002776)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
Article History
Received: 2 November 2023
Accepted: 4 July 2024
First Online: 10 July 2024
Competing interests
: The University of Pennsylvania has filed a provisional patent application US 63/559,150 entitled “Lipid-Mediated Intracellular Delivery of Recombinant bioPROTACs for Rapid Degradation of Undruggable Proteins”, with Dr. Andrew Tsourkas and Alex Chan listed as inventors. The provisional patent covers the composition of the bioPROTAC and LNP described in this manuscript and uses thereof. The University of Pennsylvania has also filed patent application W02021077066A1 entitled “Lipid and lipid nanoparticle formulation for drug delivery”, which was published on 04-22-2021, with Dr. Michael Mitchell listed as an inventor. This patent describes several of the lipids and lipid nanoparticle compositions utilized in this manuscript, namely B6, C1, C14-2, C14-4, and C14-7. The remaining authors declare no competing interest.